These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9076481)

  • 1. Diagnosis and treatment of superficial transitional cell carcinoma of the bladder: facts and perspectives.
    Kurth KH
    Eur Urol; 1997; 31 Suppl 1():10-9. PubMed ID: 9076481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and management of superficial bladder cancer.
    Amling CL
    Curr Probl Cancer; 2001; 25(4):219-78. PubMed ID: 11514784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
    Steinbach F; Schuster F
    Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
    Pham HT; Soloway MS
    Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells.
    Bonner RB; Hemstreet GP; Fradet Y; Rao JY; Min KW; Hurst RE
    Cancer; 1993 Oct; 72(8):2461-9. PubMed ID: 8402463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.
    Zietman AL; Grocela J; Zehr E; Kaufman DS; Young RH; Althausen AF; Heney NM; Shipley WU
    Urology; 2001 Sep; 58(3):380-5. PubMed ID: 11549485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis and therapy of superficial tumors of the urinary bladder].
    Babjuk M; Dvorácek J
    Cas Lek Cesk; 2002 Nov; 141(23):723-8. PubMed ID: 12650028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conservative treatment of high grade superficial bladder tumours.
    Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
    Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
    Brake M; Loertzer H; Horsch R; Keller H
    J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success.
    Lebret T; Gaudez F; Hervé JM; Barré P; Lugagne PM; Botto H
    Eur Urol; 1998; 34(1):67-72. PubMed ID: 9676417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and management of superficial bladder cancer.
    Soloway MS
    Semin Surg Oncol; 1989; 5(4):247-54. PubMed ID: 2549605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group.
    Kurth KH; Bouffioux C; Sylvester R; van der Meijden AP; Oosterlinck W; Brausi M
    Eur Urol; 2000; 37 Suppl 3():1-9. PubMed ID: 10828681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary management of stage T1 transitional cell carcinoma of the bladder.
    Soloway MS; Sofer M; Vaidya A
    J Urol; 2002 Apr; 167(4):1573-83. PubMed ID: 11912367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.
    Eure GR; Cundiff MR; Schellhammer PF
    J Urol; 1992 Feb; 147(2):376-9. PubMed ID: 1732597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The management of superficial bladder cancer.
    Dalbagni G
    Nat Clin Pract Urol; 2007 May; 4(5):254-60. PubMed ID: 17483810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.